402 related articles for article (PubMed ID: 29770618)
21. Prognostic value of peritoneal cancer index in primary advanced ovarian cancer.
Llueca A; Escrig J;
Eur J Surg Oncol; 2018 Jan; 44(1):163-169. PubMed ID: 29198495
[TBL] [Abstract][Full Text] [Related]
22. Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study.
Kim M; Suh DH; Park JY; Paik ES; Lee S; Eoh KJ; Nam JH; Lee YY; Kim JW; Kim S
J Gynecol Oncol; 2018 Jul; 29(4):e60. PubMed ID: 29770630
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
[TBL] [Abstract][Full Text] [Related]
24. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
25. Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductive surgery for advanced stage epithelial ovarian cancer.
Mikkelsen MS; Petersen LK; Blaakaer J; Marinovskij E; Rosenkilde M; Andersen G; Bouchelouche K; Iversen LH
Eur J Surg Oncol; 2021 Aug; 47(8):2134-2141. PubMed ID: 33812768
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer.
Asp M; Malander S; Bengtsson J; Sartor H; Kannisto P
Anticancer Res; 2022 May; 42(5):2541-2551. PubMed ID: 35489749
[TBL] [Abstract][Full Text] [Related]
27. Radiological assessment of Peritoneal Cancer Index on preoperative CT in ovarian cancer is related to surgical outcome and survival.
Avesani G; Arshad M; Lu H; Fotopoulou C; Cannone F; Melotti R; Aboagye E; Rockall A
Radiol Med; 2020 Aug; 125(8):770-776. PubMed ID: 32239470
[TBL] [Abstract][Full Text] [Related]
28. Development of a Novel Intra-Operative Score to Record Diseases' Anatomic Fingerprints (ANAFI Score) for the Prediction of Complete Cytoreduction in Advanced-Stage Ovarian Cancer by Using Machine Learning and Explainable Artificial Intelligence.
Laios A; Kalampokis E; Johnson R; Munot S; Thangavelu A; Hutson R; Broadhead T; Theophilou G; Nugent D; De Jong D
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765924
[TBL] [Abstract][Full Text] [Related]
29. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
30. A novel laparoscopy-based model for the prediction of optimal cytoreduction and prognosis of epithelial ovarian cancer in a Chinese population.
Tang X; Zhang X; Liu X; Zheng T; Hua K; Qiu J
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():256-262. PubMed ID: 33259994
[TBL] [Abstract][Full Text] [Related]
31. The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.
Rawert FL; Luengas-Würzinger V; Claßen-Gräfin von Spee S; Baransi S; Schuler E; Carrizo K; Dizdar A; Mallmann P; Lampe B
Arch Gynecol Obstet; 2022 Nov; 306(5):1665-1672. PubMed ID: 35357582
[TBL] [Abstract][Full Text] [Related]
32. Comparison of stage III mucinous and serous ovarian cancer: a case-control study.
Firat Cuylan Z; Karabuk E; Oz M; Turan AT; Meydanli MM; Taskin S; Sari ME; Sahin H; Ulukent SC; Akbayir O; Gungorduk K; Gungor T; Kose MF; Ayhan A
J Ovarian Res; 2018 Oct; 11(1):91. PubMed ID: 30376858
[TBL] [Abstract][Full Text] [Related]
33. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
34. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
[TBL] [Abstract][Full Text] [Related]
35. The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.
Tajik P; van de Vrie R; Zafarmand MH; Coens C; Buist MR; Vergote I; Bossuyt PMM; Kenter GG
Int J Gynecol Cancer; 2018 Mar; 28(3):453-458. PubMed ID: 29324537
[TBL] [Abstract][Full Text] [Related]
36. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
37. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Rosendahl M; Høgdall CK; Mosgaard BJ
Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
[TBL] [Abstract][Full Text] [Related]
38. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
40. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
